Pay in 4 interest-free payments of $5.10 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Its also indicated to reduce the risk of life-threatening cardiovascular events (heart attack, stroke) in people with obesity and overweight who also have heart disease
The trial data is the strongest evidence available for understanding how these medications perform
It belongs to a class of medications called GLP-1 (glucagon-like peptide-1) receptor agonists
The researchers also observed that 532 participants with BMI 35 at week 0, who had tolerated their assigned dose of medication, were then escalated to the maximum tolerated dose (9mg or 12mg) for a further 24 weeks
Adverse events were recorded at each visit
US$ 23.92
US$ 21.30
US$ 28.39
US$ 29.90
US$ 26.48
US$ 26.56
US$ 23.39
US$ 21.90
US$ 22.84
